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ABSTRACT  
Objectives Nicotinamide phosphoribosyltransferase (NAMPT)/PBEF/Visfatin exerts multiple 
functions and has been implicated in the pathogenesis of rheumatoid arthritis. To gain insight 
into its role in arthritis and given that NAMPT is identified as a novel mediator of innate 
immunity, we addressed the function of monocyte-derived NAMPT in experimental arthritis 
by selective gene knockdown in inflammatory monocytes.  
Methods siRNA uptake and NAMPT expression were determined in Ly6Chigh and Ly6Clow 
monocyte subsets following intravenous injection of siRNA against NAMPT (siNAMPT) or 
non-targeting siRNA (siCT) formulated with the DMAPAP cationic liposome into mice. Mice 
with established collagen-induced arthritis (CIA) were treated weekly after disease onset with 
siNAMPT or siCT and clinical features were assessed. T helper cell frequencies, cytokine 
production and percentage of IL-6-producing Ly6Chigh monocytes were analyzed. Using a 
coculture system consisting of purified CD14+ monocytes and autologous CD4+ T cells, 
NAMPT and cytokine production, as well as the percentage of IL-17-producing CD4+ T cells 
were determined following transfection of CD14+ monocytes with siCT or siNAMPT. 
Results Upon intravenous injection, siRNA was preferentially engulfed by Ly6Chigh 
monocytes and siRNA-mediated silencing of NAMPT expression in Ly6Chigh monocytes 
inhibited CIA progression. This effect was associated with reduced IL-6 production by 
Ly6Chigh monocytes, reduced proportion of Th17 cells and auto-antibodies titers, as well as 
decreased activation and infiltration of monocytes/macrophages and neutrophils in arthritic 
joints. Moreover, NAMPT-RNAi-silenced CD14+ monocytes were found to reduce the 
percentage of IL-17-producing CD4+ T cells in vitro.  
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Conclusions Taken together, our results show that the expression of NAMPT in Ly6Chigh 
monocytes promotes many downstream effects involved in inflammatory arthritis and 
demonstrate the utility of targeting disease-causing genes, such as NAMPT, in Ly6Chigh 
monocytes for therapeutic intervention in arthritis. 
 
Keywords: inflammatory monocytes, RNA interference, NAMPT, Th17 cells, arthritis. 
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INTRODUCTION 
Rheumatoid arthritis (RA) is a systemic inflammatory disorder that leads to the progressive 
destruction of joints. Although the etiology of RA remains unknown, many cell types and 
molecules are implicated in the pathogenesis of RA. Monocytes/macrophages are now 
believed to be local and systemic amplifiers of the disease in regards to their abundance as 
well as their paracrine effects on other immune cells and resident fibroblasts.1 The therapeutic 
efficacy of conventional anti-rheumatic drugs coincides with down-regulation of biological 
functions of monocytes/macrophages and biotherapies blocking cytokines produced 
predominantly by monocytes/macrophages are effective in the treatment of RA.2,3 The 
rheumatoid synovium contains activated monocytes/macrophages that produce large amounts 
of inflammatory mediators, including IL-1β, IL-6 and TNF-α, which contribute to synovial 
cell proliferation, maintenance of an inflammatory environment and structural joint damage. 
Notably, this cytokinic milieu promotes the development and maintenance of Th17 cells4 that 
play a pathogenic role in RA by linking T cell activation and bone resorption.5-7 Recently, it 
has been demonstrated that activated monocytes continuously migrate into the inflamed joints 
of patients with active RA8 where they acquire an activated phenotype and specifically 
promote Th17 cell differentiation, but not Th1 or Th2 cell responses.9 Thus, excessive activity 
of CD14+ monocytes participates to inflammatory disease progression, including RA, but the 
molecular pathways involved in their dysregulated function remain elusive. 
Nicotinamide phosphoribosyltransferase (NAMPT) is an ubiquitously expressed protein that 
displays multiple functions.10,11 It was originally identified as pre-B-cell colony enhancing 
factor (PBEF), a secreted factor that synergizes with IL-7 and stem cell factor to promote the 
growth of B cell precursors.12 It is also proposed as visfatin, an adipokine produced by 
visceral fat that stimulates insulin signaling.13 It may also function as an essential enzyme in 
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the NAD biosynthetic pathway that enhances cellular resistance to genotoxic/oxidative stress 
and may confer to cells of the immune system the ability to survive during stressful situations 
such as inflammation.14 Of note, NAMPT has recently been identified as a novel mediator of 
innate immunity with pro-inflammatory properties involved in the persistence of 
inflammation.15,16 NAMPT is upregulated in monocytes upon activation and induces the 
production of various pro-inflammatory cytokines including IL-6.17-19  
NAMPT has been implicated in the pathogenesis of several human diseases including RA11 
and its increased expression in peripheral blood mononuclear cells is proposed as a marker of 
chronic inflammation.20 Elevated expression of NAMPT is reported within the synovial tissue 
and blood of patients with RA and correlates with disease activity.17,21,22 Increased expression 
of NAMPT is also confirmed in mice with collagen-induced arthritis (CIA), both in serum 
and in the inflamed paws, and early in vivo blockade of NAMPT with the small molecule 
inhibitor APO866 ameliorates CIA severity.21,23 These findings support a critical role of 
NAMPT in the pathogenesis of arthritis. Nevertheless, how NAMPT expression in specific 
cell populations impacts the inflammatory response of arthritis remains unknown. 
At least two main subsets of circulating monocytes are described in humans and rodents. In 
mice, Ly6Clow monocytes survey endothelial cells and surrounding tissues for damage or viral 
infection while Ly6Chigh monocytes are highly phagocytic, secrete inflammatory mediators, 
give rise to macrophages and dendritic cells, and are involved in inflammatory disease 
progression.24,25 Given that NAMPT is expressed by both monocyte subsets and the 
importance to target the Ly6Chigh monocytes subset for therapeutic benefit in a broad range of 
inflammatory disorders,26 we undertook in vivo experiments to explore the impact of the 
RNAi-mediated silencing of NAMPT in Ly6Chigh monocytes in mouse CIA.  
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MATERIALS AND METHODS 
DMAPAP cationic lipid was synthesized as previously described27 and mixed with DOPE and 
nucleic acids as previously described.28  
DBA/1 mice were used in these studies, which were approved by the Ethics Committee on 
Animal Research of the Languedoc-Roussillon region (CE-LR-0505), and CIA was induced 
as previously described.29 Arthritis severity was graded and analyzed as previously 
described.30,46 Detailed procedures are available in Supplementary files. 
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RESULTS 
In vivo silencing of NAMPT in Ly6Chigh monocytes 
We previously reported that the cationic liposome DMAPAP efficiently delivers siRNA to 
CD11b+ monocytes and knockdown genes upon systemic administration.31 We first examined 
the respective capacity of both Ly-6Clow and Ly-6Chigh monocyte subsets to engulf siRNA 
lipoplexes upon intravenous injection (figure 1A). Mice were injected with a single dose of 
0.5mg/kg of Cy3-labeled siRNA and the percentage of siRNA-containing cells were 
monitored after 24 hours according to the gating strategy described in figure S1. While less 
than 10% of circulating Ly-6Clow monocytes engulfed the labeled siRNA (8.5% ± 1.3%), the 
presence of the siRNA was detected in 63% ± 7% of the Ly-6Chigh monocytes. Similarly, Ly-
6Chigh monocytes from the splenic reservoir engulfed the siRNA more efficiently than Ly-
6Clow monocytes (30.6% ± 6.2% and 5.4% ± 1.6% respectively). To a lesser extent, the 
presence of siRNA was also detected in macrophages and conventional DCs from the spleen 
of injected animals (see supplemental figure S2A). Of note, the siRNA was not incorporated 
into the CD45- mononuclear cells (see supplemental figure S2B) and was taken up by less 
than 1% of the circulating T and B cells (see supplemental figure S2C).  
We then evaluated the feasibility to silence NAMPT gene in Ly-6Chigh monocytes (figure 1B). 
Systemic injection of mice with DMAPAP-formulated siRNA sequences specific for mouse 
NAMPT (siNAMPT) resulted in a 66% reduction of NAMPT protein expression in Ly-6Chigh 
monocytes from blood as compared to mice injected with non-targeting control siRNA 
(siCT). Although NAMPT was expressed at lower levels in Ly-6Clow monocytes, its 
expression was not affected following the administration of siNAMPT lipoplexes. In 
agreement with the inefficient delivery of siRNA to neutrophils (less than 2% of the 
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circulating or tissue Ly-6G+ neutrophils), NAMPT levels were altered neither in the blood 
neutrophils (see supplemental figure S3A) nor in the neutrophils infiltrating arthritic joints 
(data not shown). Together, these data demonstrate that the cationic liposome DMAPAP 
efficiently delivers siRNA to the inflammatory Ly-6Chigh monocytes and silence NAMPT 
expression, as opposed to the non-inflammatory Ly-6Clow monocytes and other cells of the 
hematopoietic system, when administered intravenously in mice. 
 
RNAi-mediated silencing of NAMPT in Ly6Chigh monocytes impairs the development of 
CIA.  
Considering the importance of Ly6Chigh monocytes in inflammatory disorders and 
inflammatory properties reported for NAMPT, we investigated the effect of siNAMPT 
delivery to Ly-6Chigh monocytes in experimental arthritis. Collagen-induced arthritic (CIA) 
mice were injected intravenously with siNAMPT lipoplexes once a week after disease onset 
(figure 2). Mice treated with siNAMPT lipoplexes showed a significant improvement of 
disease features from the first day of treatment, as compared with control animals (figure 2A). 
Given that disease activity is associated with increased serum IL-6 levels, we determined the 
effect of NAMPT inhibition in Ly6Chigh monocytes on IL-6 levels by ELISA at euthanasia. 
The results showed that the protection from disease progression in the siNAMPT-treated 
group was associated with a significant decrease of circulating IL-6 levels (p=0.0485), as 
compared with mice administered with siCT lipoplexes (figure 2B). High levels of circulating 
CII-specific IgG antibodies, characterized by a high IgG2a:IgG1 ratio, are a hallmark of CIA 
and determine disease severity. We showed that, consistent with improved clinical features at 
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euthanasia in the group of siNAMPT-treated mice, and opposed to the control group, a 
significant decrease of CII-specific IgG2a:IgG1 ratio was measured (figure 2C).  
To further investigate the impact of the systemically delivered siRNA on joint inflammation, 
we determined the effect of repetitive siNAMPT lipoplex injections on cellular infiltrates. 
Consistent with the observed clinical benefit, the total number of cells infiltrating ankle joints 
of CIA mice was reduced in the siNAMPT-treated group compared with siCT-injected 
animals (figure 2D). Among these cells, decreased counts of neutrophils (see supplemental 
figure S3B), resident macrophages and inflammatory monocytes (figure 2D; see gating 
strategy in supplemental figure S1C) were observed. Interestingly, the production of TNF-α 
was significantly lower in the three cell types for CIA mice injected with siNAMPT 
lipoplexes, as compared with controls (figure 2E and S3C). These results indicate that the 
siNAMPT systemic treatment not only lead to a decrease in the number of immune cells 
infiltrating arthritic joints, but also in their activated status.  
 
In vivo inhibition of NAMPT in Ly6Chigh monocytes induces broad immunomodulation 
of arthritic conditions.  
Considering that IL-6 is abundantly expressed in arthritis by a number of cell types, including 
monocytes/macrophages, and that NAMPT induces the production of IL-6 upon monocyte 
activation, we investigated whether siRNA-mediated silencing of NAMPT in Ly6Chigh 
monocytes impacts IL-6 production by this specific cell subset in vivo under inflammatory 
conditions. Arthritic mice were injected weekly from disease onset (arthritic score > 3) with 
siNAMPT lipoplexes and spleen cells collected after 3 weeks. As we previously demonstrated 
that the CIA development is similar between PBS- and siCT-injected mice,32,33 this latter 
 11 
condition was used as control in the following experiments. Flow cytometric analysis of 
intracellular IL-6 staining showed that in vivo silencing of NAMPT in Ly-6Chigh monocytes 
during arthritis progression significantly reduced the percentage of IL-6-producing Ly-6Chigh 
monocytes (6,6 ± 0,7%), as well as the production of IL-6 by these cells (MFI=21,5 ± 0,2), as 
compared with siCT-injected mice (12,2 ± 0,8% and MFI=36,2 ± 3,3 respectively). The 
reduction of IL-6 production upon NAMPT knockdown was also confirmed by ELISA 
measurement of IL-6 protein levels (p=0,0221) in 24-hours culture supernatant of spleen cells 
as compared with control mice (figure 3B). Analysis of pro-inflammatory cytokine profiles of 
these mice showed that levels of TNF-α, IL-17A and IFN-γ were reduced in splenocytes of 
siNAMPT-treated mice compared with siCT-injected animals, while the production of the 
anti-inflammatory cytokine IL-10 was increased (figure 3B). 
Considering that IL-6 is critical for Th17 differentiation and expansion in mouse and its 
expression was reduced in Ly-6Chigh monocytes in arthritic mice treated with siNAMPT, we 
hypothesized that Th17 responses might be reduced in siNAMPT-treated CIA mice. The 
percentage of IL-17A-producing T cells and IL-17 production were measured by intracellular 
cytokine staining of CD4+ T cells (figure 3C). The results showed a reduced percentage of IL-
17A positive T cells (0,8 ± 0,1% versus 1,8 ± 0,3%) and IL-17A production (MFI=24112 ± 
1832 versus 42881 ± 2062) in the spleen of arthritic mice treated with siNAMPT lipoplexes 
relative to siCT-injected animals. Interestingly, the down-regulation of the Th17 population in 
CIA was not due to a general effect on T cell activation because neither the Th1 response, 
characterized by IFN-γ-producing CD4+ T cells, nor the frequency of CD4+CD25+Foxp3+ 
Treg cells, were significantly affected (figure 3C-D). Overall, our data indicate that 
interfering with the NAMPT/IL-6 axis in inflammatory Ly-6Chigh monocytes enables the 
modulation of pathogenic Th17 cells and reduction of inflammatory cytokines in CIA.  
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Silencing of NAMPT in human CD14+ monocytes interferes with Th17 cell expansion.  
Since one of the in vivo downstream anti-inflammatory effects of NAMPT silencing in 
Ly6Chigh monocytes is the decrease in Th17 cells, we explored in vitro whether NAMPT 
expression in human monocytes may also impact the Th17 cell responses. First, Cy3-labelled 
siRNA lipoplexes (25 nM) were added to human PBMCs to determine the uptake of the 
siRNA (figure 4A). The CD14+CD16- monocytes were found to overwhelmingly incorporate 
the siRNA (98.3% ± 0.2%), while it was only taken up by 58.4% ± 1.2% of the 
CD14dimCD16+ monocytes. Importantly, CD14+CD16- monocytes incorporated 4 times more 
siRNA than the CD14dimCD16+ monocytes (MFI=16.613 ± 185 versus 4.535 ± 272). 
Consistent with what we observed following in vivo administration to mice, human CD3+ T 
and CD19+ B lymphocytes did not reveal any positive signal for the presence of siRNA (data 
not shown). We next assessed the functional silencing in human monocytes using siNAMPT 
lipoplexes. Based on previously described procedures,34,35 CD14+ monocytes from the blood 
of healthy donors were transfected with either siCT or siNAMPT in the presence of LPS. 
NAMPT silencing was quantified at mRNA and protein levels two days after transfection. 
More than 50% of the NAMPT transcripts and 30% of the protein levels were down-regulated 
upon siNAMPT application compared with controls, as shown by RT-qPCR and flow 
cytometry respectively (figure 4B). Down-regulation of NAMPT expression in CD14+ 
monocytes was associated with a significant decrease of both IL-6 and TNF-α expression 
levels (figure 4C). Next, to assess the effect of NAMPT silencing in CD14+ monocytes on 
Th17 cell expansion, CD14+ monocytes were co-cultured 48 hours after transfection with 
autologous purified CD4+ T cells and the percentage of IL-17-producing CD4+ T cells was 
monitored 5 days later. Addition of siNAMPT-transfected CD14+ monocytes to autologous 
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CD4+ T cells resulted in a significant decrease in the percentage of IL-17A-producing CD4+ T 
cells, as opposed to siCT-transfected monocytes (figure 4D). These data show that inhibition 
of NAMPT gene expression in human CD14+ monocytes reduces the expansion of Th17 cells.  
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DISCUSSION  
NAMPT exerts multiple functions in a variety of physiological processes and its 
overexpression has been implicated in the pathogenesis of a number of inflammatory 
disorders, including cancer, atherosclerosis, diabetes and RA.11 Numerous studies have shown 
that NAMPT regulates inflammatory mediators and apoptosis. For instance, NAMPT protects 
macrophages from ER stress-induced apoptosis by activating an IL-6/Stat3 signaling 
pathway.32 We recently reported that NAMPT is overexpressed by FLS of RA patients and 
stimulates the production of IL-6, IL-8, MMP-1 and MMP-3 in RASF, as well as IL-6 and 
TNF-α in monocytes.17 Monocytes, a key cell type in RA pathogenesis, are themselves a 
source of NAMPT, which expression is up-regulated under inflammatory conditions18 and 
able to induce IL-6 transcription in these cells,17-19,36,37 further substantiating the autocrine 
role of NAMPT in inducing IL-6 expression by monocytes. Nevertheless, the mechanisms 
underlying the deleterious effect of NAMPT in the inflammatory process of RA remain 
unclear.  
In the present study, we found that systemic administration of siRNA-containing lipoplexes 
able to deliver and silence NAMPT in Ly6Chigh monocytes ameliorated disease features in a 
mouse model of RA. Significant clinical benefit was demonstrated by reduced systemic and 
local inflammatory markers of arthritis, including reduced serum IL-6 levels, decreased anti-
bCII antibody titers and marked reduction in the number of Th17 cells, as well as in the 
number and activation status of Ly-6Chigh monocytes, macrophages and neutrophils 
infiltrating the arthritic joints. In arthritic joints, TNF-α is one of the most deleterious 
cytokine implicated in inflammatory processes, and we showed that NAMPT down-regulation 
in Ly6Chigh monocytes leads to a significant decrease of TNF-α expression by their main 
producers, i.e. monocytes and macrophages. Our in vitro and in vivo studies performed on 
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human CD14+ and mouse Ly6Chigh monocytes respectively showed that one of the 
downstream effects of knocking down NAMPT expression in this cell subset was a decreased 
IL-6 expression by these cells, associated with an impaired Th17 cell expansion. We cannot 
exclude that NAMPT silencing may affect other genes than IL-6 and TNF-α and is likely to 
involve other mechanisms of immune modulation accounting for the observed beneficial 
effects. However, we can exclude that the defect of Ly-6Chigh monocyte recruitment observed 
in inflamed joints from siNAMPT-treated mice was not due to a reduced expression of the 
CCR2/MCP1 axis (data not shown). Interestingly, although NAMPT gene silencing in Ly-
6Chigh monocytes was associated with a markedly reduced frequency of IL-17A-producing 
CD4+ T cells, the numbers and percentage of Th1 and Treg cells were unchanged. Consistent 
with these findings, it has been reported that the administration of an anti-IL-6R suppressed 
arthritis and inhibited Th17 differentiation but did not alter Th1, Th2 or Treg cell levels.36,38 
Importantly, clinical benefits demonstrated in the trials in which RA patients were treated 
with the neutralizing anti-IL-6R mAb tocilizumab showed reduced IL-6 serum levels, 
dampened T- and B-lymphocyte-mediated inflammatory responses, and suppressed x-ray 
progression of disease. In conclusion, we demonstrate that NAMPT expression in Ly-6Chigh 
monocytes participates to arthritis progression, not only confirming that NAMPT plays an 
important role in inflammatory responses, but also suggesting that Ly-6Chigh monocytes are 
among key cellular mediators of these pro-inflammatory actions.  
Rheumatoid arthritis (RA) is a chronic inflammatory disorder in which the CD14+ monocytes 
continuously migrate into the injured joint tissue8,39,40 and act as local and systemic amplifiers 
of disease through the multitude and abundance of their paracrine/autocrine acting mediators.1 
Their numbers are increased in clinically affected joints and correlate with clinical signs,41 
and thus strategies aiming at interfering with this specific cell subset to provide therapeutic 
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benefit are intensely challenged. To date, two main approaches have been used to impact on 
monocytes’ survival or recruitment, either by their depleting or by antagonizing chemokine 
receptors important in their trafficking.42 Although these strategies showed promising results 
in animal models of RA, none of them were effective in RA patients.43 The present work 
suggests that alternative strategies might be envisioned such as silencing the expression of a 
master gene implicated in pro-inflammatory functions of Ly6Chigh monocytes to modify their 
activation status, their capacity to prime T and B cell responses, to activate neutrophils, and to 
alter overall disease progression. The present study thus indicates that strategies based on the 
“Trojan monocyte” for drug delivery to inflamed sites are of particular interest in arthritis, 
and may be applied to a broad range of inflammatory disorders.  
As NAMPT is expressed in many cell types and exerts multiple functions, the latter strategy 
however requires overcoming the major challenges in achieving efficient in vivo RNAi, i.e. 
being able to deliver the therapeutic siRNA to those cells. Previously, we have shown that, 
upon intravenous administration, the cationic liposome DMAPAP formulation distributes 
siRNAs to the myeloid compartment.33 Here, we further refined the siRNA distribution to the 
respective monocyte subsets and demonstrate that the siRNA is preferentially taken up by the 
Ly-6Chigh monocyte subset, as opposed to the Ly-6Clow monocytes, in the blood, spleen, liver 
and arthritic joints (data not shown), resulting in efficient and specific silencing of NAMPT in 
Ly-6Chigh monocytes. Although to lesser extent, siRNA uptake was also detected in tissue 
resident macrophages and cDC, thought to arise from Ly-6Chigh monocytes under 
inflammatory conditions.44 Importantly, we show here that siRNA was not efficiently taken 
up by non-hematopoietic cells and only very weakly incorporated into T and B lymphocytes 
or neutrophils (<2% of positive cells) and that no variation in NAMPT expression was 
evidenced in Ly-6Clow monocytes. Our in vitro data on human PBMCs show that the liposome 
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formulation enables efficient delivery of siRNA to classical CD14+CD16- monocytes. To a 
lesser extent, the siRNA was also taken up by non-classical CD14dimCD16+ monocytes. 
However the amount of siRNA engulfed by this subset (showed by MFI) is very low 
compared to CD14+CD16- monocytes. Although comparing efficiencies between in vitro and 
in vivo experiments is not relevant, these data suggest that different mechanisms might be 
involved in cationic liposome uptake by monocyte subsets, and perhaps between human and 
mouse monocytes, that need to be further characterized.  
Several studies have demonstrated the importance of Ly6Chigh monocytes in the pathogenesis 
of inflammatory disorders. In experimental autoimmune encephalomyelitis (EAE), a mouse 
model of multiple sclerosis, Ly-6Chigh monocytes accumulate in the blood and migrate to the 
central nervous system (CNS) before disease onset, where they differentiate into DCs and 
macrophages in EAE lesions.45 Moreover, increased numbers of circulating Ly-6Chigh 
monocytes are associated with enhanced disease severity. In a mouse model of myocardial 
infarct, Ly-6Chigh monocytes were found to first migrate to the site of inflammation during the 
acute phase.46 Finally, when the accumulation of Ly-6Chigh monocytes in sites of 
inflammation was prevented by silencing CCR2 expression, a reduction of atherosclerotic 
lesions in apoE-/- mice and of myocardial ischemia injury was reported, as well as a 
prolonged islet graft survival.26 Altogether, these studies underscore the contribution of Ly-
6Chigh monocytes to pathological events in a broad range of inflammatory and autoimmune 
disorders. The specific implication of Ly-6Chigh monocyte was not however determined in 
arthritis. Here, using the experimental mouse CIA model, we show that Ly-6Chigh monocytes 
also play a key role in arthritis pathogenesis.  
Our findings identify NAMPT as a critical gene that can be targeted to modulate pro-
inflammatory cytokines produced by Ly-6Chigh monocytes, to impact on their crosstalk with 
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other immune cells and to interfere with inflammatory responses in arthritis. The downstream 
molecular mechanisms responsible for the anti-inflammatory effects of NAMPT-mediated 
silencing in Ly6Chigh monocytes remain however to be elucidated.  
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